Pre-made Abrezekimab benchmark antibody ( Fab, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-004

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-004 Category Tag

Product Details

Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abrezekimab (formerly VR 942) a biologic immunomodulatory product, is being developed by UCB and Vectura Group for the treatment of severe inflammatory.

Products Name (INN Index)

Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody

INN Name

Abrezekimab

Target

IL13

Format

Fab

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2017

Companies

UCB

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Asthma

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL13

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide